Oli Raises $6.5M Series A3 to Advance Maternal‑fetal Monitoring

Why It Matters

Early‑warning wearables like Oli could dramatically reduce maternal and fetal mortality by enabling clinicians to intervene before complications become critical, reshaping obstetric care worldwide.

Key Takeaways

• Oli raised $6.5M Series A3, total $13M private capital
• Device captures millions of data points from 10 maternal‑fetal biosensors
• Predictive Maternal‑Fetal Signal tech flags 15 possible birth complications
• Clinical trial across Australia and US nearing 1,000 participants
• Launch slated for Australia and US by end of 2027

Pulse Analysis

Maternal health has long lagged behind other medical specialties in terms of technology adoption, yet the global market for obstetric monitoring is projected to exceed $2 billion by 2030. Oli’s entry arrives at a moment when hospitals and birth centers are seeking data‑driven solutions to address persistent challenges such as postpartum haemorrhage, fetal distress and pre‑eclampsia. By embedding a wireless, multi‑sensor platform into the birthing process, the startup not only captures granular physiological signals but also feeds them into a predictive algorithm that continuously updates risk scores, offering clinicians actionable insights in real time.

The core of Oli’s advantage lies in its patented Predictive Maternal‑Fetal Signal technology, which translates raw sensor streams into clinically meaningful alerts. Unlike traditional intermittent monitoring, the device operates without restricting maternal movement, preserving natural labour dynamics while amassing a dataset that grows with each birth. This continuous learning model promises to improve predictive accuracy over time, positioning Oli as a potential standard‑of‑care tool for early detection of up to fifteen complications, from obstructed labour to cardiovascular risks in mothers.

Securing $6.5 million in Series A3 funding underscores investor confidence in the commercial viability of AI‑enabled wearables for obstetrics. The capital will fund the final phases of a 1,000‑patient pivotal trial, support TGA and FDA submissions, and scale manufacturing ahead of a dual‑market launch in Australia and the United States by late 2027. Successful regulatory clearance could unlock reimbursement pathways and accelerate adoption across public and private health systems, ultimately expanding access to high‑precision maternal monitoring for diverse populations worldwide.

Deal Summary

Australian medtech startup Oli announced a $6.5 million Series A3 round, backed by Scale Investors, Clare Ventures and the University of Sydney. The funding will accelerate development of its wearable maternal‑fetal monitoring device, support clinical trials in Australia and the US, and fund regulatory submissions and manufacturing. The raise brings Oli’s total private capital to $13 million.